Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.925 USD | +0.28% | +15.65% | +53.34% |
May. 13 | Janney Starts TScan Therapeutics With Buy Rating, $11 Price Target | MT |
May. 13 | TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+53.34% | 509M | |
+34.54% | 50.85B | |
+0.41% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.94% | 26.11B | |
-21.65% | 19.13B | |
+8.42% | 13.05B | |
+27.13% | 12.16B | |
+24.48% | 12.08B |
- Stock Market
- Equities
- TCRX Stock
- News TScan Therapeutics, Inc.
- TScan Therapeutics Receives FDA Approval for TSC-203-A0201's Investigational New Drug Application